Evidence map›Paper›PMID 26745975›Full record

ArticleEnvironmental health and preventive medicine2016

XPC intron11 C/A polymorphism as a risk factor for prostate cancer.

Yoshihiro Yoshino, Shouhei Takeuchi, Takahiko Katoh, Yoshiki Kuroda

Abstract read
In one paragraph

Article in Environmental health and preventive medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. The correlation between polymorphisms in theTranslational pediatrics · 2021
    Article
  4. Noninvasive circulating tumor cell and urine cellularTranslational cancer research · 2019
    Article
  5. Article
  6. Article
  7. Lack of Associations betweenBioMed research international · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yoshihiro YoshinoDepartment of Public Health, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Shouhei TakeuchiDepartment of Public Health, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Takahiko KatohDepartment of Public Health, Faculty of Life Science, University of Kumamoto, 1-1-1 Honjyoh, Chuou-ku, Kumamoto, 860-8556, Japan.
Yoshiki KurodaDepartment of Public Health, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan. ykuroda@med.miyazaki-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesDNA repair genes play an important role in protection against environmental and endogenous DNA damage, and constitute the first line of defense against cancer. Xeroderma pigmentosum complementation group C (XPC) is involved in the damage recognition step during nucleotide excision repair. The relationship between XPC intron11 C/A polymorphism and cancer risk has not been widely studied. Hence, this study evaluated the relationship between the XPC intron11 C/A polymorphism and prostate cancer risk. MATERIALS AND

methodsThis hospital-based cohort consisted of 152 patients with prostate cancer and 142 male controls. The XPC intron11 C/A genotype was determined using the PCR-RFLP method. Medical, occupational, and cigarette-smoking history was obtained from each participant using questionnaires.

resultsLogistic regression analysis revealed that compared to controls, the frequencies of the A/A and C/A genotypes were significantly higher than those of the C/C genotype in cancer patients (OR = 2.03, 95% confidence interval (CI) 1.03-3.98 and OR = 1.91, 95% CI 1.13-3.24, respectively). We also found that the frequency of the A/A genotype was significantly higher in cancer cases than in controls among non-smokers (OR = 7.7, 95% CI 1.38-42.88, compared to the C/C genotype).

conclusionWe found that the XPC intron11 C/A polymorphism was associated with an increased risk of prostate cancer. Among non-smokers, the A/A genotype was significantly more prevalent in prostate cancer patients than in controls.

Indexed as

Polymorphism, GeneticAgedAged, 80 and overDNA-Binding ProteinsGenotypeHumansJapanMaleMiddle AgedPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthProstatic NeoplasmsRisk FactorsSmokingDNA-Binding ProteinsXPC protein, humanCancer riskDNA repair geneProstate cancerXeroderma pigmentosumXPC-PAT

Identifiers

PMID26745975
PMCPMC4771637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.